NCT03560245: A reported trial by Neurotrope Bioscience, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03560245 |
|---|---|
| Title | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 20, 2018 |
| Completion date | July 25, 2019 |
| Required reporting date | July 24, 2020, midnight |
| Actual reporting date | June 17, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |